The 2023 European Society of Cardiology guidelines for managing CVD in patients with diabetes recommend that in patients with CAD and T2DM, SGLT2-I or GLP-1 analogues should be added to the treatment regimen, irrespective of HbA1c control (10, 31, 32). The gene discussed is GCG; the disease is coronary artery disorder.